Pfizer in the spotlight (part II)

Pfizer's obesity drug fails; market shifts to other GLP-1s.

Based on Phase 2b data presented last week, Pfizer's twice-oral danuglipron for obesity faced setbacks due to high discontinuation rates from gastrointestinal (GI) side effects, prompting a market shift towards other oral GLP-1 drugs and raising speculation about Pfizer's potential acquisitions in this sector, while a real-world study showed slightly lo…